Imaging agent scans in advanced bladder, breast and lung cancers
Tests an imaging agent in adults with advanced urothelial, breast or lung cancer.
Plain-language title generated from the registry record
Registry title: Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
Key facts
- Where
- Johannesburg and Pretoria, South AfricaSee the 2 sites
- Phase
- Early phase 1
Where in South Africa
- JohannesburgJohannesburg, South AfricaNo longer taking part
- PretoriaPretoria, South AfricaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RayzeBio, Inc.
- Trial code
- NCT07671092
- Record updated
- 13 October 2026
- Original description
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.Read full original descriptionShow less
A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Metastatic Urothelial Cancer (UC), Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer, Triple-Negative Breast Cancer (TNBC), and Non-Small-Cell Lung Cancer (NSCLC)
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
Inclusion: Are at least 18 years old at the time of signing the informed consent form (ICF); Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
Exclusion: For Women of Childbearing Potential: Are pregnant or breastfeeding; Note: Additional criteria may apply and will be assessed by the study site.